Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
Roche and Hitachi High-Tech extend their long-standing partnership TOKYO, May 28, 2024 - (JCN Newswire) - Hitachi High-Tech Corporation announced that Roche and Hitachi High-Tech have extended their partnership, committing to at least 10 years of additional collaboration. Bringing t...
Roche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing PR Newswire Renewed partnership combines best in class engineering capabilities with cutting edge science to accelerate the availability of new soluti...
2024-05-26 15:19:39 ET Summary Eli Lilly's shares reached new all-time highs after the company increased full-year revenue and EPS guidance. The company's growth is currently supply-constrained and the growth of tirzepatide in the near- and possibly medium-term should only be limi...
2024-05-26 13:36:00 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety The FTC Cracks Down On Novo Nordisk's Ozempic SA Asks: Is Eli Lilly or Novo ...
2024-05-26 04:30:00 ET Summary Parnassus Investments is a fundamental, bottoms-up investment firm offering responsible investment funds to the public. Parnassus Investments integrates comprehensive ESG evaluations with fundamental financial analysis to select investments. The Fund...
– The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting – – Approximately 40% of people with HR-positive breast...
2024-05-20 17:17:41 ET Summary Moderna's individualized neoantigen therapy, mRNA-4157, is a cancer vaccine with potential in multiple cancer types. mRNA-4157 has produced compelling results in stage III/IV melanoma patients, where a combination with pembrolizumab reduced the risk ...
2024-05-20 09:58:45 ET More on PTC Therapeutics PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts PTC Therapeutics, Inc. (PTCT) Q1 2024 Earnings Call Transcript PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript PTC Therapeuti...
2024-05-20 08:20:00 ET Summary The mean weight loss in a Phase 1b trial of the GLP/GIP against CT-388 (once-a-week injection for 24 weeks) has just read out at 18.8%, with (apparently) no safety signals. Amgen sort-of-announced positive results on its candidate, MariTide. Boeh...
2024-05-19 15:05:03 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: Great Time To Divest Before It Potentially Crashes Eli Lilly Remains Expensive Here - Minimal Margin Of Safety The FTC Cracks Down On Novo Nordisk's Ozempic Biopharma M&A surges year ...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
– Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) – – Safety data were consistent with the known safety profile for Susvimo in people...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...